Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free PRTA Stock Alerts

Prothena (PRTA) Financials

Prothena logo
$9.16 +0.55 (+6.39%)
As of 12:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Prothena

Annual Income Statements for Prothena

This table shows Prothena's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -81 -160 -153 -156 -78 -111 67 -117 -147 -122 -244
Consolidated Net Income / (Loss)		 -81 -160 -153 -156 -78 -111 67 -117 -147 -122 -244
Net Income / (Loss) Continuing Operations		 -81 -160 -153 -156 -78 -111 67 -117 -147 -122 -244
Total Pre-Tax Income 		-80 -159 -158 -156 -77 -111 72 -126 -160 -129 -201
Total Operating Income		 -80 -160 -155 -159 -86 -113 72 -132 -191 -155 -215
Total Gross Profit		 1.61 1.06 28 0.96 0.81 0.85 201 54 91 135 9.68
Total Revenue		 1.61 1.06 28 0.96 0.81 0.85 201 54 91 135 9.68
Operating Revenue		 1.61 1.06 28 0.96 0.81 0.85 201 54 91 135 9.68
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 82 161 183 160 87 114 129 185 282 290 224
Selling, General & Admin Expense		 23 41 48 42 36 39 46 50 62 67 59
Research & Development Expense		 58 120 135 101 51 75 82 136 221 223 135
Restructuring Charge		 - 0.00 0.00 16 -0.06 - - - 0.00 0.00 30
Total Other Income / (Expense), net		 0.03 0.57 -2.35 2.74 8.40 1.31 -0.05 5.95 31 26 14
Interest Expense		 -0.20 -0.56 0.14 -2.69 -8.20 -1.37 -0.04 -6.35 -31 -26 -14
Other Income / (Expense), net		 -0.17 0.02 -2.21 0.05 0.20 -0.06 -0.10 -0.40 -0.46 -0.19 -0.33
Income Tax Expense		 0.70 1.14 -4.37 -0.47 0.38 -0.28 4.95 -8.66 -13 -6.62 43
Basic Earnings per Share		 ($2.66) ($4.66) ($4.07) ($3.93) ($1.95) ($2.78) $1.51 ($2.47) ($2.76) ($2.27) ($4.53)
Weighted Average Basic Shares Outstanding		 30.33M 34.35M 37.65M 39.56M 39.88M 39.92M 44.23M 47.37M 53.22M 53.77M 53.83M
Diluted Earnings per Share		 ($2.66) ($4.66) ($4.07) ($3.93) ($1.95) ($2.78) $1.38 ($2.47) ($2.76) ($2.27) ($4.53)
Weighted Average Diluted Shares Outstanding		 30.33M 34.35M 37.65M 39.56M 39.88M 39.92M 48.46M 47.37M 53.22M 53.77M 53.83M
Weighted Average Basic & Diluted Shares Outstanding		 30.33M 34.35M 37.65M 39.56M 39.88M 39.92M 46.69M 52.56M 53.72M 53.83M 53.83M

Quarterly Income Statements for Prothena

This table shows Prothena's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -67 -72 67 -59 -58 -60 -126 -37 -22 33 -19
Consolidated Net Income / (Loss)		 -67 -72 67 -59 -58 -60 -126 -37 -22 33 -19
Net Income / (Loss) Continuing Operations		 -67 -72 67 -59 -58 -60 -126 -37 -22 33 -19
Total Pre-Tax Income 		-71 -74 65 -60 -60 -61 -81 -37 -22 33 -19
Total Operating Income		 -79 -82 58 -67 -65 -66 -85 -40 -24 30 -21
Total Gross Profit		 0.32 0.05 132 0.97 2.12 2.83 4.42 2.42 0.02 51 1.01
Total Revenue		 0.32 0.05 132 0.97 2.12 2.83 4.42 2.42 0.02 51 1.01
Operating Revenue		 0.32 0.05 132 0.97 2.12 2.83 4.42 2.42 0.02 51 1.01
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 79 82 74 67 67 68 89 43 24 21 22
Selling, General & Admin Expense		 17 17 16 17 17 18 16 13 13 13 11
Research & Development Expense		 62 64 58 51 50 51 41 29 15 13 8.80
Restructuring Charge		 - - 0.00 0.00 - 0.00 33 0.48 - -4.24 2.41
Total Other Income / (Expense), net		 7.90 7.09 6.47 6.68 5.40 4.21 3.65 3.33 2.62 2.69 2.52
Interest Expense		 -8.10 -7.17 -6.52 -6.74 -5.39 -4.35 -3.79 -3.35 -2.65 -2.42 -2.55
Other Income / (Expense), net		 -0.21 -0.08 -0.05 -0.07 0.01 -0.14 -0.14 -0.02 -0.02 0.27 -0.03
Income Tax Expense		 -3.14 -2.20 -2.04 -0.84 -1.55 -1.18 45 -0.37 0.01 0.00 0.00
Basic Earnings per Share		 ($1.25) ($1.34) $1.24 ($1.10) ($1.07) ($1.12) ($2.34) ($0.68) ($0.39) $0.61 ($0.36)
Weighted Average Basic Shares Outstanding		 53.22M 53.71M 53.77M 53.79M 53.77M 53.83M 53.83M 53.83M 53.83M 53.71M 52.15M
Diluted Earnings per Share		 ($1.22) ($1.34) $1.22 ($1.10) ($1.05) ($1.12) ($2.34) ($0.68) ($0.39) $0.60 ($0.36)
Weighted Average Diluted Shares Outstanding		 53.22M 53.71M 55.04M 53.79M 53.77M 53.83M 53.83M 53.83M 53.83M 54.11M 52.15M
Weighted Average Basic & Diluted Shares Outstanding		 53.72M 53.77M 53.78M 53.81M 53.83M 53.83M 53.83M 53.83M 53.83M 52.35M 51.34M

Annual Cash Flow Statements for Prothena

This table details how cash moves in and out of Prothena's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 77 20 31 10 -53 -80 282 132 -92 -149 -164
Net Cash From Operating Activities		 -59 -116 -131 -28 -53 -80 93 -109 -134 -150 -164
Net Cash From Continuing Operating Activities		 -59 -116 -131 -28 -53 -80 93 -109 -134 -150 -164
Net Income / (Loss) Continuing Operations		 -81 -160 -153 -156 -78 -111 67 -117 -147 -122 -244
Consolidated Net Income / (Loss)		 -81 -160 -153 -156 -78 -111 67 -117 -147 -122 -244
Depreciation Expense		 0.81 2.43 3.07 3.22 1.56 1.51 1.12 0.74 0.93 0.89 0.90
Amortization Expense		 - - 0.00 0.00 5.26 5.46 5.69 6.00 7.48 2.69 2.81
Non-Cash Adjustments To Reconcile Net Income		 11 26 28 31 19 17 19 25 35 44 35
Changes in Operating Assets and Liabilities, net		 11 16 -9.36 93 -0.98 6.89 -0.32 -24 -30 -75 42
Net Cash From Investing Activities		 -1.38 -17 -3.52 -1.73 -0.55 -0.20 -0.58 -0.46 -2.77 -0.30 -0.14
Net Cash From Continuing Investing Activities		 -1.38 -17 -3.52 -1.73 -0.55 -0.20 -0.58 -0.46 -2.77 -0.30 -0.14
Purchase of Property, Plant & Equipment		 -1.38 -17 -3.63 -1.77 -0.56 -0.20 -0.58 -0.46 -2.81 -0.30 -0.14
Sale of Property, Plant & Equipment		 0.00 0.00 0.11 0.04 0.01 - 0.00 0.00 0.04 0.00 0.00
Net Cash From Financing Activities		 137 153 165 40 0.23 0.22 190 241 45 1.55 -0.14
Net Cash From Continuing Financing Activities		 137 153 165 40 0.23 0.22 190 241 45 1.55 -0.14
Issuance of Common Equity		 131 129 150 40 0.00 0.00 78 173 21 0.00 0.00
Other Financing Activities, net		 5.65 25 15 0.29 0.23 0.22 112 69 24 1.55 -0.14
Cash Income Taxes Paid		 0.44 0.58 0.29 -1.00 1.58 1.37 0.58 2.66 1.55 3.17 0.93

Quarterly Cash Flow Statements for Prothena

This table details how cash moves in and out of Prothena's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -52 -72 16 -45 -48 -53 -47 -41 -23 22 -45
Net Cash From Operating Activities		 -51 -73 16 -45 -48 -53 -46 -41 -23 29 -25
Net Cash From Continuing Operating Activities		 -51 -74 16 -45 -48 -53 -46 -41 -23 29 -29
Net Income / (Loss) Continuing Operations		 -67 -72 67 -59 -58 -60 -126 -37 -22 33 -19
Consolidated Net Income / (Loss)		 -67 -72 67 -59 -58 -60 -126 -37 -22 33 -19
Depreciation Expense		 0.28 0.22 0.23 0.23 0.22 0.22 0.23 0.23 0.22 0.18 0.20
Non-Cash Adjustments To Reconcile Net Income		 9.55 12 11 10 9.87 10 13 5.93 4.38 1.73 1.93
Changes in Operating Assets and Liabilities, net		 4.35 -14 -63 2.53 -0.60 -4.38 66 -10 -9.13 -5.76 -14
Net Cash From Investing Activities		 -1.51 -0.10 -0.14 -0.01 -0.04 -0.04 -0.09 -0.01 - 0.00 -0.65
Net Cash From Continuing Investing Activities		 -1.51 -0.10 -0.14 -0.01 -0.04 -0.04 -0.09 -0.01 - 0.00 -0.65
Purchase of Property, Plant & Equipment		 -1.55 -0.10 -0.14 -0.01 -0.04 -0.04 -0.09 -0.01 - 0.00 -0.65
Net Cash From Financing Activities		 0.48 0.84 0.44 0.33 -0.06 -0.05 -0.07 -0.02 - -6.95 -16
Net Cash From Continuing Financing Activities		 0.48 0.89 0.39 0.33 -0.06 -0.05 -0.07 -0.02 - -6.95 -16
Repurchase of Common Equity		 - - - - - - - - - -6.95 -16
Cash Income Taxes Paid		 1.17 0.02 1.56 0.84 0.76 0.00 0.94 0.00 -0.01 0.00 -0.62

Annual Balance Sheets for Prothena

This table presents Prothena's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 385 460 496 42 419 333 609 758 696 547 327
Total Current Assets		 377 391 426 0.00 378 299 585 719 639 485 315
Cash & Equivalents		 371 387 418 - 376 295 579 710 619 471 308
Prepaid Expenses		 6.31 4.26 8.47 - 2.58 2.54 5.72 8.69 14 14 7.66
Plant, Property, & Equipment, net		 3.86 56 55 4.98 3.87 2.55 2.01 1.73 3.84 3.08 2.14
Total Noncurrent Assets		 3.97 12 15 37 37 31 23 37 53 59 9.47
Other Noncurrent Operating Assets		 1.12 2.19 6.90 29 27 19 15 19 19 15 9.47
Total Liabilities & Shareholders' Equity		 385 460 496 -561 419 333 609 758 696 547 327
Total Liabilities		 25 95 89 34 146 149 143 136 135 60 46
Total Current Liabilities		 22 41 37 11 18 26 33 50 57 49 41
Accounts Payable		 4.52 13 14 - 1.24 4.12 3.69 9.27 25 7.77 5.88
Accrued Expenses		 13 19 14 - 5.83 9.04 6.35 11 15 13 4.33
Current Deferred Revenue		 - - - - - 0.00 7.66 11 0.00 8.85 2.66
Other Current Liabilities		 4.90 8.56 9.92 11 11 13 16 19 17 18 28
Total Noncurrent Liabilities		 2.35 53 52 23 129 123 110 86 78 12 5.49
Other Noncurrent Operating Liabilities		 0.13 - 0.00 23 18 13 6.94 0.55 11 8.23 5.49
Commitments & Contingencies		 - - - - - - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 361 365 407 -594 273 184 466 622 561 487 280
Total Preferred & Common Equity		 361 365 407 -594 273 184 466 622 561 487 280
Total Common Equity		 361 365 407 -594 273 184 466 622 561 487 280
Common Stock		 490 655 850 - 945 967 1,182 1,455 1,541 1,589 1,627
Retained Earnings		 -129 -289 -442 -594 -672 -783 -716 -833 -980 -1,102 -1,346
Other Equity Adjustments		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Balance Sheets for Prothena

This table presents Prothena's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 742 721 747 623 646 595 495 399 353 350 303
Total Current Assets		 700 677 691 566 586 535 436 385 340 339 292
Cash & Equivalents		 686 659 671 547 564 519 418 371 331 329 288
Prepaid Expenses		 14 16 13 18 22 16 18 14 9.13 9.74 3.82
Plant, Property, & Equipment, net		 1.92 2.17 2.43 3.67 3.49 3.25 2.87 2.69 2.46 1.96 2.49
Total Noncurrent Assets		 39 41 54 54 56 57 56 11 10 8.73 8.08
Other Noncurrent Operating Assets		 18 15 24 17 17 16 11 11 10 8.73 8.08
Total Liabilities & Shareholders' Equity		 742 721 747 623 646 595 495 399 353 350 303
Total Liabilities		 134 139 130 121 64 61 58 75 58 37 16
Total Current Liabilities		 49 72 53 43 47 46 48 68 51 33 12
Accounts Payable		 13 14 19 14 9.29 10 16 12 11 4.30 1.94
Accrued Expenses		 14 19 18 17 16 10 13 11 9.54 4.61 0.55
Current Deferred Revenue		 9.32 25 0.32 0.00 8.03 8.83 7.90 5.10 2.69 1.63 0.62
Other Current Liabilities		 13 14 16 12 14 17 12 40 29 22 8.55
Total Noncurrent Liabilities		 85 67 76 78 17 14 9.20 6.93 6.20 4.76 4.03
Other Noncurrent Operating Liabilities		 0.00 0.00 8.92 10 9.54 8.88 7.58 6.93 6.20 4.76 4.03
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 607 582 617 502 582 534 438 324 295 313 287
Total Preferred & Common Equity		 607 582 617 502 582 534 438 324 295 313 287
Total Common Equity		 607 582 617 502 582 534 438 324 295 313 287
Common Stock		 1,487 1,516 1,530 1,555 1,567 1,579 1,600 1,613 1,620 1,626 1,619
Retained Earnings		 -880 -934 -913 -1,052 -985 -1,044 -1,163 -1,288 -1,325 -1,314 -1,332
Other Equity Adjustments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for Prothena

This table displays calculated financial ratios and metrics derived from Prothena's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 31,522,750.00 34,488,428.00 38,446,761.00 39,863,711.00 39,896,561.00 39,921,413.00 46,593,782.00 - - - 53,829,982.00
DEI Adjusted Shares Outstanding		 31,522,750.00 34,488,428.00 38,446,761.00 39,863,711.00 39,896,561.00 39,921,413.00 46,593,782.00 - - - 53,829,982.00
DEI Earnings Per Adjusted Shares Outstanding		 -2.56 -4.64 -3.99 -3.90 -1.95 -2.78 1.44 - - - -4.53
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -96.84% -34.35% 2,508.44% -96.53% -14.76% 4.79% 23,414.30% -73.13% 69.50% 47.92% -92.84%
EBITDA Growth		 -1,297.37% -98.10% 1.72% -0.78% 49.43% -34.49% 174.36% -259.14% -46.22% 17.44% -39.76%
EBIT Growth		 -1,148.16% -99.13% 1.29% -0.85% 46.16% -31.92% 163.72% -283.58% -45.12% 19.19% -38.92%
NOPAT Growth		 -1,102.24% -99.58% 2.68% -2.32% 46.05% -31.55% 184.93% -237.40% -45.21% 19.09% -38.87%
Net Income Growth		 -1,027.44% -98.62% 4.29% -1.57% 50.09% -43.08% 160.26% -274.62% -25.72% 16.81% -99.57%
EPS Growth		 -817.24% -75.19% 12.66% 3.44% 50.38% -42.56% 149.64% -278.99% -11.74% 17.75% -99.56%
Operating Cash Flow Growth		 -8,479.80% -98.38% -12.85% 78.45% -87.33% -51.72% 215.23% -217.51% -23.05% -12.06% -9.02%
Free Cash Flow Firm Growth		 -1,037.62% -196.28% 15.83% 36.47% 165.35% -233.99% 197.63% -273.39% -39.81% -11.81% 41.03%
Invested Capital Growth		 -168.75% 359.59% 59.59% -78.88% -1,284.90% -9.65% -0.29% 21.84% 33.44% 126.42% -274.13%
Revenue Q/Q Growth		 -51.49% -11.42% 0.21% -3.54% 8.24% 13.89% 0.41% 945.89% -35.19% 1.36% -17.83%
EBITDA Q/Q Growth		 -16.44% -17.83% 0.65% 13.76% 0.55% -7.20% -3.44% 20.73% -73.42% 7.47% 17.06%
EBIT Q/Q Growth		 -16.29% -18.12% 0.72% 13.50% -0.56% -6.74% -3.67% 19.86% -69.20% 8.21% 15.91%
NOPAT Q/Q Growth		 -16.14% -18.64% 1.25% 13.39% -0.61% -6.65% -3.61% 20.06% -69.67% 8.10% 15.94%
Net Income Q/Q Growth		 -15.88% -18.28% 0.74% 13.98% 1.15% -8.98% -3.55% 25.26% -100.85% 7.22% 12.97%
EPS Q/Q Growth		 -5.56% -15.35% 3.78% 15.12% 0.51% -8.59% 32.69% 19.02% -100.00% 6.97% 12.72%
Operating Cash Flow Q/Q Growth		 -5.97% -18.30% -4.56% 39.25% 11.32% -6.08% -3.51% 13.84% -52.44% 2.13% 13.01%
Free Cash Flow Firm Q/Q Growth		 -15.85% -11.78% -3.12% -218.05% 313.87% -0.34% -7.48% 12.76% -42.26% 2.82% 15.75%
Invested Capital Q/Q Growth		 -0.69% -7.49% 8.00% 113.23% -1.65% -5.98% -3.12% 2.88% -6.90% 2.90% 24.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -4,934.72% -14,890.33% -561.05% -16,292.25% -9,665.97% -12,405.51% 39.23% -232.28% -200.37% -111.84% -2,181.60%
Operating Margin		 -4,974.30% -15,121.80% -564.17% -16,634.03% -10,527.89% -13,216.18% 35.88% -244.05% -209.08% -114.36% -2,216.44%
EBIT Margin		 -4,984.88% -15,120.38% -572.19% -16,629.01% -10,503.81% -13,223.45% 35.84% -244.79% -209.58% -114.49% -2,219.83%
Profit (Net Income) Margin		 -5,016.30% -15,176.11% -556.84% -16,297.91% -9,542.63% -13,029.78% 33.39% -216.95% -160.92% -90.49% -2,520.57%
Tax Burden Percent		 100.88% 100.72% 97.23% 99.70% 100.49% 99.75% 93.12% 93.11% 91.62% 94.87% 121.54%
Interest Burden Percent		 99.76% 99.65% 100.09% 98.30% 90.41% 98.79% 100.06% 95.19% 83.80% 83.32% 93.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.88% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -1,411.19% -325.25% -446.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -1,397.55% -312.62% -484.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 1,367.09% 285.58% 613.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -24.78% -44.10% -39.67% 166.45% 48.35% -48.65% 20.61% -21.50% -24.85% -23.34% -63.62%
Cash Return on Invested Capital (CROIC)		 0.00% -572.31% -371.16% -316.68% 0.00% 0.00% 0.00% 0.00% 0.00% -1,174.85% 0.00%
Operating Return on Assets (OROA)		 -23.24% -37.75% -32.93% -58.98% -37.06% -29.99% 15.26% -19.30% -26.33% -24.89% -49.20%
Return on Assets (ROA)		 -23.39% -37.89% -32.05% -57.80% -33.66% -29.55% 14.21% -17.11% -20.22% -19.67% -55.86%
Return on Common Equity (ROCE)		 -24.78% -44.10% -39.67% 166.45% 48.35% -48.65% 20.61% -21.50% -24.85% -23.34% -63.62%
Return on Equity Simple (ROE_SIMPLE)		 -22.35% -43.82% -37.63% 26.19% -28.46% -60.40% 14.37% -18.80% -26.19% -25.12% 0.00%
Net Operating Profit after Tax (NOPAT)		 -56 -112 -109 -111 -60 -79 67 -92 -134 -108 -150
NOPAT Margin		 -3,482.01% -10,585.26% -394.92% -11,643.82% -7,369.52% -9,251.32% 33.42% -170.84% -146.36% -80.05% -1,551.51%
Net Nonoperating Expense Percent (NNEP)		 -7.42% -13.64% -12.63% 37.54% 15.57% -9.59% -0.01% -3.86% -2.00% -2.59% -24.10%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -14.80% -23.82% -22.22% -53.57%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,437.77% 3,891.56% 175.25% 4,448.38% 4,390.17% 4,537.28% 23.09% 92.57% 67.68% 49.72% 613.30%
R&D to Revenue		 3,636.53% 11,330.24% 488.92% 10,595.08% 6,245.21% 8,778.90% 41.02% 251.48% 241.40% 164.64% 1,392.52%
Operating Expenses to Revenue		 5,074.30% 15,221.80% 664.17% 16,734.03% 10,627.89% 13,316.18% 64.12% 344.05% 309.08% 214.36% 2,316.44%
Earnings before Interest and Taxes (EBIT)		 -80 -160 -157 -159 -86 -113 72 -132 -191 -155 -215
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -79 -157 -154 -156 -79 -106 79 -125 -183 -151 -211
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.95 4.64 3.54 0.00 2.31 2.61 4.94 4.69 3.47 1.53 1.83
Price to Tangible Book Value (P/TBV)		 5.95 4.64 3.54 0.00 2.31 2.61 4.94 4.69 3.47 1.53 1.83
Price to Revenue (P/Rev)		 1,336.04 1,608.04 52.38 429.94 775.88 562.08 11.48 54.07 21.34 5.51 53.09
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 34.37 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.91% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 52.86 26.17 47.33 0.00 0.00 0.00 0.00 0.00 17.63 0.00
Enterprise Value to Revenue (EV/Rev)		 1,105.43 1,289.94 39.07 429.94 314.30 214.21 8.59 40.89 14.56 2.03 21.33
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 21.89 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 23.97 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 25.70 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 18.60 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 4.97 0.00 25.58 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.14 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.14 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -0.98 -0.91 -1.27 -0.71 -1.47 -1.35 -1.19 -1.12 -1.04 -1.02
Leverage Ratio		 1.06 1.16 1.24 -2.88 -1.44 1.65 1.45 1.26 1.23 1.19 1.14
Compound Leverage Factor		 1.06 1.16 1.24 -2.83 -1.30 1.63 1.45 1.20 1.03 0.99 1.06
Debt to Total Capital		 0.00% 12.32% 11.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 12.32% 11.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 87.68% 88.77% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.33 -0.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 2.14 2.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.33 -0.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.46 -0.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 3.01 3.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.46 -0.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 52.39 9.65 8.40 -25.05 0.71 -1.49 9.79 11.88 6.92 4.88 -0.24
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 16.99 9.53 11.41 0.00 21.36 11.58 17.48 14.34 11.24 10.01 7.72
Quick Ratio		 16.70 9.42 11.18 0.00 21.21 11.43 17.31 14.17 10.97 9.72 7.53
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -50 -147 -124 -79 51 -69 67 -117 -163 -183 -108
Operating Cash Flow to CapEx		 -4,240.23% -698.45% -3,725.73% -1,635.40% -9,683.55% -41,001.02% 16,105.22% -23,452.80% -4,828.92% -50,352.35% -118,536.23%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -873.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -923.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -948.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.06 0.00 0.00 0.00 0.43 0.08 0.13 0.22 0.02
Accounts Receivable Turnover		 1.42 3.07 131.67 0.00 0.00 20.55 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.46 0.04 0.49 0.03 0.18 0.27 87.91 28.80 32.83 39.08 3.71
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 257.57 118.84 2.77 0.00 0.00 17.76 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 257.57 118.84 2.77 0.00 0.00 17.76 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -9.92 26 41 8.68 -103 -113 -113 -88 -59 16 -27
Invested Capital Turnover		 -0.24 0.13 0.82 0.04 -0.02 -0.01 -1.78 -0.54 -1.24 -6.25 -1.68
Increase / (Decrease) in Invested Capital		 -6.23 36 15 -32 -111 -9.92 -0.33 25 30 74 -43
Enterprise Value (EV)		 1,776 1,361 1,075 411 256 183 1,723 2,204 1,330 274 207
Market Capitalization		 2,147 1,696 1,441 411 632 479 2,302 2,915 1,950 745 514
Book Value per Share		 $11.44 $10.59 $10.59 ($14.91) $6.84 $4.61 $10.00 $12.86 $10.46 $9.05 $5.21
Tangible Book Value per Share		 $11.44 $10.59 $10.59 ($14.91) $6.84 $4.61 $10.00 $12.86 $10.46 $9.05 $5.21
Total Capital		 361 417 459 -594 273 184 466 622 561 487 280
Total Debt		 0.00 51 52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 51 52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -371 -336 -366 0.00 -376 -297 -579 -710 -620 -471 -308
Capital Expenditures (CapEx)		 1.38 17 3.52 1.73 0.55 0.20 0.58 0.46 2.77 0.30 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -37 -29 -11 -15 -23 -28 -41 -38 -34 -33
Debt-free Net Working Capital (DFNWC)		 355 350 389 -11 361 273 551 669 582 437 274
Net Working Capital (NWC)		 355 350 389 -11 361 273 551 669 582 437 274
Net Nonoperating Expense (NNE)		 25 48 45 44 18 32 0.05 25 13 14 94
Net Nonoperating Obligations (NNO)		 -371 -340 -366 603 -376 -297 -579 -710 -620 -471 -308
Total Depreciation and Amortization (D&A)		 0.81 2.43 3.07 3.22 6.82 6.98 6.80 6.74 8.41 3.59 3.70
Debt-free, Cash-free Net Working Capital to Revenue		 -958.25% -3,472.61% -104.16% -1,109.84% -1,850.37% -2,731.07% -13.83% -76.90% -41.36% -25.51% -342.64%
Debt-free Net Working Capital to Revenue		 22,102.49% 33,202.56% 1,413.41% -1,109.84% 44,307.25% 32,055.80% 274.89% 1,240.98% 637.40% 323.26% 2,833.02%
Net Working Capital to Revenue		 22,102.49% 33,202.56% 1,413.41% -1,109.84% 44,307.25% 32,055.80% 274.89% 1,240.98% 637.40% 323.26% 2,833.02%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.66) ($4.66) ($4.07) ($3.93) ($1.95) ($2.78) $1.51 ($2.47) ($2.76) ($2.27) ($4.53)
Adjusted Weighted Average Basic Shares Outstanding		 34.34M 35.03M 38.54M 39.86M 39.91M 39.99M 44.23M 47.37M 53.22M 53.77M 53.83M
Adjusted Diluted Earnings per Share		 ($2.66) ($4.66) ($4.07) ($3.93) ($1.95) ($2.78) $1.38 ($2.47) ($2.76) ($2.27) ($4.53)
Adjusted Weighted Average Diluted Shares Outstanding		 34.34M 35.03M 38.54M 39.86M 39.91M 39.99M 48.46M 47.37M 53.22M 53.77M 53.83M
Adjusted Basic & Diluted Earnings per Share		 ($2.66) ($4.66) ($4.07) ($3.93) ($1.95) ($2.78) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 30.33M 34.35M 37.65M 39.56M 39.88M 39.92M 46.69M 52.56M 53.72M 53.83M 53.83M
Normalized Net Operating Profit after Tax (NOPAT)		 -56 -112 -109 -100 -60 -79 67 -92 -134 -108 -129
Normalized NOPAT Margin		 -3,482.01% -10,585.26% -394.92% -10,460.42% -7,374.77% -9,251.32% 33.42% -170.84% -146.36% -80.05% -1,334.08%
Pre Tax Income Margin		 -4,972.68% -15,067.68% -572.71% -16,347.12% -9,496.07% -13,062.95% 35.86% -233.01% -175.64% -95.39% -2,073.82%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -1,108.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -765.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -1,133.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -790.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Prothena

This table displays calculated financial ratios and metrics derived from Prothena's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - 53,826,982.00 53,826,982.00 53,829,982.00 53,829,982.00 53,832,982.00 52,353,237.00
DEI Adjusted Shares Outstanding		 - - - - - 53,826,982.00 53,826,982.00 53,829,982.00 53,829,982.00 53,832,982.00 52,353,237.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -1.12 -2.34 -0.68 -0.40 0.61 -0.36
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -99.37% -97.69% 3,184.75% -98.86% 571.84% 5,556.00% -96.65% 148.97% -99.01% 1,706.36% -77.15%
EBITDA Growth		 -5,836.52% -48.77% 190.37% -621.08% 16.02% 20.37% -244.36% 39.67% 62.88% 147.04% 75.23%
EBIT Growth		 -19,629.32% -44.52% 187.58% -746.84% 17.57% 19.46% -245.32% 39.53% 62.67% 146.11% 75.07%
NOPAT Growth		 -40,116.93% -44.75% 229.34% -487.93% 17.34% 19.56% -198.37% 39.50% 62.71% 165.42% 75.06%
Net Income Growth		 -1,162.78% -54.15% 222.51% -369.32% 14.11% 16.67% -288.03% 38.07% 62.75% 154.36% 85.22%
EPS Growth		 -862.50% -50.56% 218.45% -389.47% 13.93% 16.42% -291.80% 38.18% 62.86% 153.57% 84.62%
Operating Cash Flow Growth		 -925.68% -53.93% 135.52% -574.79% 6.40% 26.95% -390.37% 10.23% 51.20% 154.11% 45.95%
Free Cash Flow Firm Growth		 -240.42% -39.56% 47.50% -387.06% -41.74% -22.94% 115.58% 119.53% 121.42% 159.96% -1,169.09%
Invested Capital Growth		 33.44% 42.29% 122.58% 127.44% 126.42% 143.43% -364.73% -337.44% -274.13% -185.32% 97.24%
Revenue Q/Q Growth		 -99.63% -84.18% 263,928.00% -99.27% 118.87% 33.21% 56.29% -45.36% -99.13% 243,157.14% -98.02%
EBITDA Q/Q Growth		 -704.32% -6.84% 171.95% -212.18% 2.61% -0.22% -29.06% 52.64% 40.03% 227.00% -168.67%
EBIT Q/Q Growth		 -864.79% -3.66% 171.47% -214.15% 2.54% -1.28% -28.97% 52.50% 39.83% 225.10% -169.74%
NOPAT Q/Q Growth		 -557.93% -3.84% 205.51% -177.32% 2.43% -1.05% -29.03% 52.44% 39.85% 277.27% -149.18%
Net Income Q/Q Growth		 -408.01% -7.06% 192.59% -188.21% 1.77% -3.86% -108.93% 70.95% 40.92% 251.56% -156.79%
EPS Q/Q Growth		 -421.05% -9.84% 191.04% -190.16% 4.55% -6.67% -108.93% 70.94% 42.65% 253.85% -160.00%
Operating Cash Flow Q/Q Growth		 -636.28% -43.13% 121.85% -383.14% -5.72% -11.70% 13.16% 12.46% 42.53% 223.87% -186.74%
Free Cash Flow Firm Q/Q Growth		 -252.76% -6.95% 59.76% -220.87% -2.66% 7.23% 105.10% 302.17% 12.58% 159.72% -190.92%
Invested Capital Q/Q Growth		 -6.90% 22.70% 139.14% -15.14% 2.90% 27.08% -338.56% 23.88% 24.54% 37.74% 92.27%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -24,107.91% -162,780.00% 44.36% -6,771.86% -3,013.42% -2,291.80% -1,912.53% -1,657.72% -114,319.05% 59.69% -2,072.97%
Operating Margin		 -24,846.52% -163,056.00% 44.22% -6,857.01% -3,056.85% -2,318.99% -1,914.39% -1,666.25% -115,252.38% 58.80% -2,089.21%
EBIT Margin		 -24,911.39% -163,210.00% 44.18% -6,863.81% -3,056.43% -2,323.94% -1,917.62% -1,667.21% -115,357.14% 59.33% -2,092.48%
Profit (Net Income) Margin		 -21,353.16% -144,478.00% 50.67% -6,082.58% -2,729.91% -2,128.54% -2,845.41% -1,513.08% -102,804.76% 64.05% -1,839.90%
Tax Burden Percent		 95.55% 97.04% 103.14% 98.60% 97.40% 98.08% 155.34% 98.99% 100.05% 100.00% 100.01%
Interest Burden Percent		 89.71% 91.22% 111.18% 89.87% 91.70% 93.38% 95.52% 91.68% 89.08% 107.97% 87.92%
Effective Tax Rate		 0.00% 0.00% -3.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,350.12% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,349.40% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,340.32% 0.00%
Return on Equity (ROE)		 -24.85% -31.07% -8.75% -22.90% -23.34% -23.46% -66.85% -67.63% -63.62% 9.80% -14.39%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -902.20% -1,244.02% -1,174.85% -821.68% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -3,129.99% -21,346.53% 14.05% -1,363.89% -664.42% -573.17% -37.97% -41.46% -2,556.59% 8.13% -325.24%
Return on Assets (ROA)		 -2,682.92% -18,896.53% 16.11% -1,208.65% -593.44% -524.97% -56.33% -37.63% -2,278.40% 8.78% -285.98%
Return on Common Equity (ROCE)		 -24.85% -31.07% -8.75% -22.90% -23.34% -23.46% -66.85% -67.63% -63.62% 9.80% -14.39%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -34.32% -8.75% -24.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -55 -57 60 -47 -45 -46 -59 -28 -17 30 -15
NOPAT Margin		 -17,392.56% -114,139.20% 45.61% -4,799.91% -2,139.80% -1,623.29% -1,340.07% -1,166.38% -80,676.67% 58.79% -1,462.45%
Net Nonoperating Expense Percent (NNEP)		 -1.88% -2.46% 1.09% -2.09% -2.30% -2.96% -14.22% -1.97% -1.19% 0.72% -1.16%
Return On Investment Capital (ROIC_SIMPLE)		 -9.79% - - - -9.33% -10.49% -18.26% -9.55% -6.04% 9.61% -5.15%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 5,360.76% 34,928.00% 12.22% 1,727.84% 793.59% 622.28% 359.95% 548.16% 60,219.05% 24.79% 1,079.11%
R&D to Revenue		 19,585.76% 128,228.00% 43.56% 5,229.18% 2,363.26% 1,796.71% 916.67% 1,198.26% 69,457.14% 24.72% 871.09%
Operating Expenses to Revenue		 24,946.52% 163,156.00% 55.78% 6,957.01% 3,156.85% 2,418.99% 2,014.39% 1,766.25% 115,352.38% 41.20% 2,189.21%
Earnings before Interest and Taxes (EBIT)		 -79 -82 58 -67 -65 -66 -85 -40 -24 30 -21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -76 -81 59 -66 -64 -65 -85 -40 -24 30 -21
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.47 2.65 1.91 1.68 1.53 1.52 1.01 1.78 1.83 1.67 1.79
Price to Tangible Book Value (P/TBV)		 3.47 2.65 1.91 1.68 1.53 1.52 1.01 1.78 1.83 1.67 1.79
Price to Revenue (P/Rev)		 21.34 14.89 5.11 6.75 5.51 4.83 31.60 44.58 53.09 9.03 9.40
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 30.67 25.20 17.63 12.57 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 14.56 8.76 2.51 2.85 2.03 1.80 0.00 16.51 21.33 3.34 4.11
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.12 -1.11 -1.05 -1.03 -1.04 -1.03 -1.03 -1.03 -1.02 -1.00 -1.08
Leverage Ratio		 1.23 1.23 1.17 1.17 1.19 1.19 1.15 1.14 1.14 1.13 1.15
Compound Leverage Factor		 1.10 1.12 1.31 1.05 1.09 1.11 1.10 1.05 1.01 1.22 1.01
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.46 4.96 9.96 7.25 5.42 4.43 -1.62 0.85 1.68 4.67 14.50
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.24 13.08 12.54 11.52 10.01 9.00 5.68 6.61 7.72 10.43 25.05
Quick Ratio		 10.97 12.63 12.07 11.19 9.72 8.62 5.48 6.43 7.53 10.13 24.72
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -85 -90 -36 -117 -120 -111 5.67 23 26 67 -61
Operating Cash Flow to CapEx		 -3,294.90% -70,923.30% 11,160.14% -502,066.67% -111,097.67% -127,054.76% -53,883.72% -405,650.00% 0.00% 0.00% -3,841.87%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.13 0.13 0.32 0.20 0.22 0.25 0.02 0.02 0.02 0.14 0.16
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 32.83 31.90 76.82 46.90 39.08 42.16 3.35 4.12 3.71 23.99 21.07
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -59 -45 18 15 16 20 -47 -36 -27 -17 -1.30
Invested Capital Turnover		 -1.24 -1.44 -7.12 -6.68 -6.25 -10.73 -0.71 -1.14 -1.68 39.97 -2.25
Increase / (Decrease) in Invested Capital		 30 33 97 70 74 65 -65 -51 -43 -37 46
Enterprise Value (EV)		 1,330 781 546 380 274 248 -45 195 207 194 224
Market Capitalization		 1,950 1,329 1,110 900 745 666 327 525 514 523 513
Book Value per Share		 $10.46 $9.35 $10.82 $9.94 $9.05 $8.13 $6.03 $5.48 $5.21 $5.81 $5.48
Tangible Book Value per Share		 $10.46 $9.35 $10.82 $9.94 $9.05 $8.13 $6.03 $5.48 $5.21 $5.81 $5.48
Total Capital		 561 502 582 534 487 438 324 295 280 313 287
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -620 -548 -564 -519 -471 -418 -371 -331 -308 -329 -288
Capital Expenditures (CapEx)		 1.55 0.10 0.14 0.01 0.04 0.04 0.09 0.01 0.00 0.00 0.65
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -38 -25 -25 -31 -34 -30 -54 -42 -33 -23 -7.84
Debt-free Net Working Capital (DFNWC)		 582 523 539 489 437 388 318 289 274 307 280
Net Working Capital (NWC)		 582 523 539 489 437 388 318 289 274 307 280
Net Nonoperating Expense (NNE)		 13 15 -6.67 12 13 14 67 8.37 4.65 -2.69 3.81
Net Nonoperating Obligations (NNO)		 -620 -548 -564 -519 -471 -418 -371 -331 -308 -329 -288
Total Depreciation and Amortization (D&A)		 2.54 0.22 0.23 0.89 0.91 0.91 0.23 0.23 0.22 0.18 0.20
Debt-free, Cash-free Net Working Capital to Revenue		 -41.36% -28.30% -11.46% -23.02% -25.51% -21.91% -519.94% -358.94% -342.64% -39.31% -14.37%
Debt-free Net Working Capital to Revenue		 637.40% 585.54% 248.21% 366.38% 323.26% 281.08% 3,071.93% 2,448.14% 2,833.02% 529.31% 514.13%
Net Working Capital to Revenue		 637.40% 585.54% 248.21% 366.38% 323.26% 281.08% 3,071.93% 2,448.14% 2,833.02% 529.31% 514.13%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.25) ($1.34) $1.24 ($1.10) ($1.07) ($1.12) ($2.34) ($0.68) ($0.39) $0.61 ($0.36)
Adjusted Weighted Average Basic Shares Outstanding		 53.22M 53.71M 53.77M 53.79M 53.77M 53.83M 53.83M 53.83M 53.83M 53.71M 52.15M
Adjusted Diluted Earnings per Share		 ($1.22) ($1.34) $1.22 ($1.10) ($1.05) ($1.12) ($2.34) ($0.68) ($0.39) $0.60 ($0.36)
Adjusted Weighted Average Diluted Shares Outstanding		 53.22M 53.71M 55.04M 53.79M 53.77M 53.83M 53.83M 53.83M 53.83M 54.11M 52.15M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 53.72M 53.77M 53.78M 53.81M 53.83M 53.83M 53.83M 53.83M 53.83M 52.35M 51.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -55 -57 41 -47 -45 -46 -36 -28 -17 26 -13
Normalized NOPAT Margin		 -17,392.56% -114,139.20% 30.95% -4,799.91% -2,139.80% -1,623.29% -823.64% -1,152.49% -80,676.67% 50.49% -1,295.14%
Pre Tax Income Margin		 -22,347.47% -148,880.00% 49.12% -6,168.66% -2,802.68% -2,170.19% -1,831.79% -1,528.45% -102,757.14% 64.06% -1,839.70%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Prothena’s latest results show lower operating expenses and a smaller net loss, but revenue remains highly volatile and the company continues to consume cash. In Q2 2026, revenue was just $1.0 million, down sharply from $51.1 million in Q1 2026 and $4.4 million in the restated Q2 2025 results. This is also far below the $132.0 million reported in Q2 2024, highlighting Prothena’s dependence on potentially irregular collaboration, licensing or milestone revenue.

  • Operating losses improved substantially year over year. Q2 2026 operating loss was $21.1 million, compared with an $84.6 million loss in Q2 2025 and a $40.2 million loss in Q3 2025.
  • Expense reductions are visible across the income statement. Selling, general and administrative expense fell to $10.9 million from $15.9 million in Q2 2025, while research and development expense declined to $8.8 million from $40.5 million. The latest quarter also included a $2.4 million restructuring charge.
  • The net loss narrowed considerably. Prothena reported a Q2 2026 net loss of $18.6 million, or $0.36 per share, versus a restated net loss of $125.8 million, or $2.34 per share, in Q2 2025.
  • Operating cash burn improved from the prior-year period. Net cash used in operating activities was $25.0 million in Q2 2026, versus $46.3 million in Q2 2025 and $40.6 million in Q3 2025.
  • The balance sheet remains lightly leveraged. Prothena had $288.2 million of cash and equivalents against total liabilities of $15.7 million at June 30, 2026. Current assets of $292.0 million were approximately 25 times current liabilities of $11.7 million.
  • Share repurchases reduced the share count. Prothena spent $15.6 million on common-stock repurchases in Q2 2026, following $6.9 million in Q1. Weighted average basic shares declined to 52.1 million from 53.7 million in Q2 2025, which can support per-share results if the buybacks continue to be made at attractive prices.
  • Cash flow was volatile during the first half of 2026. Operating cash flow was positive by $28.9 million in Q1 but turned negative by $25.0 million in Q2. The Q2 decline included a $14.2 million unfavorable change in operating assets and liabilities, so quarterly cash flow may not fully represent the underlying burn rate.
  • Interest and investment-related income helped offset operating losses. Q2 2026 total other income was reported at $2.5 million, partially reducing the pretax loss. However, these items are not a substitute for recurring revenue or sustainable operating profitability.
  • Revenue generation remains the primary weakness. Q2 2026 revenue covered only a small fraction of the company’s $22.1 million in operating expenses. Prothena has reported several quarters of minimal revenue, with the notable exception of the $132.0 million Q2 2024 quarter.
  • Cash reserves are declining over the longer term. Cash and equivalents fell from $564.1 million in Q2 2024 and $371.4 million in Q2 2025 to $288.2 million in Q2 2026. Although the company still has substantial liquidity, continued operating losses, research spending and share repurchases will reduce that cushion over time.

Overall, Prothena’s cost base has contracted and its losses have improved from the exceptionally weak 2025 periods. However, the company is not yet generating consistent revenue or positive operating cash flow. Investors should focus on the durability of future collaboration and milestone revenue, the pace of cash consumption, and whether reduced spending affects the development of Prothena’s pipeline.

The supplied financial history includes several restated income statements and cash-flow statements, so comparisons with earlier periods should be treated cautiously. The data also represents selected quarterly snapshots rather than complete annual statements.

10/09/26 10:38 AM ETAI Generated. May Contain Errors.

Prothena Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Prothena's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Prothena's net income appears to be on a downward trend, with a most recent value of -$244.09 million in 2025, falling from -$80.61 million in 2015. The previous period was -$122.31 million in 2024. See Prothena's forecast for analyst expectations on what's next for the company.

Prothena's total operating income in 2025 was -$214.64 million, based on the following breakdown:
  • Total Gross Profit: $9.68 million
  • Total Operating Expenses: $224.32 million

Over the last 10 years, Prothena's total revenue changed from $1.61 million in 2015 to $9.68 million in 2025, a change of 502.6%.

In the past 13 quarters, Prothena's cash and equivalents has ranged from $288.19 million in Q2 2026 to $686.18 million in Q1 2023, and is currently $288.19 million as of their latest financial filing in Q2 2026.

Prothena had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Prothena's book value per share changed from 11.44 in 2015 to 5.21 in 2025, a change of -54.5%.


Related Companies

Financial statements for NASDAQ:PRTA last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel